Stargardt Macular Degeneration Clinical Trials

Find Stargardt Macular Degeneration Clinical Trials Near You

A Phase 1, Randomized, Double-Masked, Placebo-Controlled, Single-Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CITY-RBP4 Administered Subcutaneously in Healthy Volunteers and Participants With Stargardt Disease Type 1 (STGD1)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 45
Healthy Volunteers: t
View:

• Willing and able to provide written informed consent form

• Be aged 18 to 45 years (inclusive) at the time of signing the informed consent form

• Generally healthy on medical history, exam, labs, and ECG

• BCVA 20/25 or better in each eye

• Serum retinol above protocol threshold

• Body weight ≥40 kg and BMI of 18.0 to 32.0 kg/m2

• Men and WOCBP must agree to use highly effective methods of contraception or practice abstinence from 30 days before the first dose of CITY-RBP4, throughout the study, and for at least 180 days after treatment with CITY-RBP4 or the last study visit, whichever is longer; men must refrain from donating or banking sperm during the same period

• Female participants who are not WOCBP should meet at least 1 of the following criteria: have undergone a documented hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy; have medically confirmed ovarian failure, or achieved postmenopausal status

• Participants aged 12 to 45 years

• Clinical diagnosis of STGD1 with documented ABCA4 pathogenic/likely pathogenic variant

• Minimum BCVA is required in the study eye

• Subjects must have a defined aggregate atrophic lesion in 1 or both eyes

• Body weight ≥40 kg

• Able to complete key ophthalmic safety assessments and comply with study precautions

Locations
Other Locations
Australia
Nucleus Network
RECRUITING
Melbourne
Contact Information
Primary
City Therapeutics
clinicaltrials@citytx.com
857-219-5440
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2028-04
Participants
Target number of participants: 48
Treatments
Experimental: CITY-RBP4 in Healthy Adults (Part A)
Placebo_comparator: In Healthy Adults (Part A)
Experimental: CITY-RBP4 in Participants with STGD1 (Parts B & C)
Placebo_comparator: In Participants with STGD1 (Parts B & C)
Related Therapeutic Areas
Sponsors
Leads: City Therapeutics

This content was sourced from clinicaltrials.gov

Similar Clinical Trials